That's right, so this was a critical foundational trial to...

That's right, so this was a critical foundational trial to enable those further developments. As Jen summarised on slide 11, the trial has:

1. Established an efficacy signal.
2. Shown absence of GvHD = universal therapy.
3. Demonstrated cell persistence up to 28 days.
4. Successful cell expansion = efficient manufacturing.
5. Provided the basis for further developments.

In other words the platform works and is safe. This data package opens the door for combination trials and further developments including CAR targeting. Another point which went slightly under the radar is that it also opens the door to collaborative out-licensing opportunities.